AdreView FDA Approval History
FDA Approved: Yes (First approved September 19, 2008)
Brand name: AdreView
Generic name: iobenguane I 123
Dosage form: Injection
Company: GE Healthcare
Treatment for: Diagnosis and Investigation
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.
Development Timeline for AdreView
|Sep 19, 2008||FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.